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Abstract 
The lipid profile of ten liver cancer patients were compared with the lipid profile of ten normal subjects at the 
Chemical Pathology Department of the University Teaching Hospital Ado-Ekiti, Ekiti State Nigeria., with a view to 
establish whether liver cancer have significant effect on lipid profile. The parameters examined were Total 
Cholesterol (TC), Triglyceride (TG), High density lipoprotein cholesterol (HDL-C), Low density lipoprotein 
cholesterol (LDL-C) and Atherogenic risk ratio (TC:HDL-C). The results obtained  were subjected to statistical 
analysis to examine the level of Significance difference between lipid profile of liver cancer patients and those of 
normal subjects. The results of analysis of variance (ANOVA) under 0.05 (5%) probability with F-table value at 
degree of freedom 1, 18 being  4.41 showed that level of TC (F-calculated = 5.56) and LDL-C (F-calculated = 6.73) 
were significant while the level of HDL-C (F-calculated = 1.78), TG (F -calculated = 0.70) and TC:HDL-C 
(F-calculated 0.02) were not significant . The Duncan’s multiple range test also showed that the difference between 
means of TC (DBM = 1.114) of the liver cancer patients and the normal subjects was significant when compared to 
0.993 Least Significant Range (LSR). Similarly the difference between means of LDL-C (DBM = 0.946) of the liver 
cancer patients and the normal subjects was significant when compared to 0.766 LSR. However, there were no 
significant difference in the DBM and LSR of TG, HDL-C and TC: HDL-C since DBM was less than LSR in those 
cases. The results of Students T- test from the statistical analysis conformed to the results of the ANOVA and 
Duncan’ Multiple Range Test.  Thus, from the statistical analyses, it could be concluded that liver cancer have 
significant effect on the TC and the LDL-C with little or no effect on the TG, the HDL-C and the Atherogenic risk 
ratio of the subjects examined in this study. Since high level of LDL-C indicates high risk of Coronary Heart Disease 
(CHD), it was therefore recommended that lipid profile of liver cancer patients should be monitored to prevent CHD 
among liver cancer patients.     
 
1.0 Introduction 
Liver is one of the most important organs in energy metabolism. Most plasma apolipoproteins, endogenous 
lipids and lipoproteins are synthesized in the liver (Bell, 1979), which depends on the integrity of cellular functions of 
liver (Eisenberg, 1975). Under normal physiological conditions, liver ensures homeostasis of lipid and lipoprotein 
metabolism. Hepatic cellular damage and Hepatocellular Carcinoma (HCC) impairs these processes, leading to 
alterations in plasma lipid and lipoprotein patterns. Mortality due to liver cancer is the fifth common malignant tumor 
worldwide, and it is closely related to the infections of hepatitis B virus (HBV) (Buendia, 1992) and hepatitis C virus 
(HCV). HBV proteins, such as the hepatitis B X protein (HBx) that is large hepatitis B surface protein could regulate 
transcription of many candidate genes for liver carcinogenesis. As HBV and HCV infections are quite common in 
China and in other Southeast Asian countries, the mortality of HCC is 20,4/100,000 in the population of China, 
corresponding to about 18.8% of all fatal malignant tumors (Parkin et al., 2001). Hepatic diseases differ from most 
other causes of secondary dyslipidemia in that the circulating lipoproteins are not only present in abnormal amounts 
but they frequently also have abnormal composition, electrophoretic mobility and appearance. It has been 
demonstrated that patients suffering from acute hepatitis B could have lipid disorders, for instance, decreased plasma 
HDL (Colombo et al., 1982). The aberrations of lipid metabolism are often seen in the chronic hepatitis B infection too. 
HDL and its major apolipoproteins, apoAI and apoAII, are frequently reduced in the patients suffering from cirrhosis 
or HCC. Decrease in the level of serum LDL cholesterol in patients with liver disease was significantly correlated to 
the increasing severity of the disease (Cooper et al., 1996). Decreased serum levels of cholesterol and apoAI may 
indicate a poor prognosis.  
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The patients with HCC frequently have other liver diseases such as chronic hepatitis and cirrhosis. All these 
conditions (hepatitis and cirrhosis of the liver) are often associated with plasma lipid and lipoprotein aberrations. It has 
been demonstrated that plasma triglycerides (TG) decreased by 20–30% in the patients with HCC. In contrast, Alsabti 
(Alsabti, 1979) reported that serum TG in HCC patients were increased when compared to those with cirrhosis. 
Alsabti, 1979 reported that plasma TG levels in HCC patients were not significantly different compared with controls. 
These results emphasize the fact that changes of plasma lipid profile may not always imply the presence of HCC and 
one need to exercise caution in interpreting these results.  
It is known that lipids and lipoprotein metabolism could be regulated by cytokines. For instance, interleukin-6 
(IL-6), tumor necrosis factor (TNF-α), IL-1 may inhibit TG synthesis. Tumor cells are known to produce large amounts 
of pro-inflammatory cytokines that, in turn, may suppress plasma TG levels. Cooper, et al., 1996 reported that IL-1 
profoundly affects lipid metabolism by delaying intestinal absorption and decreasing tissue uptake. IL-2 could induce 
severe hypocholesterolemia that is mediated by the inhibition of lecithin:cholesteryl acyltransferase (LCAT) activity. 
IL-1 and IL-6 significantly decreased microsomal triglyceride transfer protein (MTP) mRNA levels in HepG2 cells. It 
is believed that MTP is related to the synthesis of very low density lipoprotein (VLDL). In addition, these cytokines 
could also decrease lipolysis in vivo. Similar results have been reported in other types of cancer.  
About 80% endogenous cholesterols are synthesized in the hepatocellular microsomes that contain 
cholesterol synthesis enzymes. In HCC and chronic liver diseases the synthesis and metabolism of cholesterol are 
impaired. It leads to a decrease in plasma cholesterol levels (Cooper et al., 1996). Motta et al., 2003 reported in their 
publication that the relationship between serum cholesterol and occurrence of cancers in 9021 employees aged from 35 
to 64 years old. No evidence of association of serum cholesterol level with total cancer mortality was seen by Log-rank 
trend test. But there was a significant negative correlation between serum cholesterol level and HCC (P < 0.05). This 
negative correlation also existed between serum cholesterol level and chronic hepatitis and liver cirrhosis. Similar 
results were described in patients with gastrointestinal cancer, however, lower cholesterol levels are not related to the 
cancer stages. Decreased serum cholesterol concentrations were also found in other cancers, which are probably 
related to the increased consumption of cholesterol by the tumor cells, as cholesterol levels in the hepatoma tissues 
were doubled compared to the control tissues. In addition, it has been reported that synthesis of cholesterol is reduced 
under cancers and moderate increases of serum cholesterol levels and increased body mass index (BMI) may have a 
protective effect on cancer mortality. It was observed that the plasma HDL-cholesterol was inversely correlated to the 
cholesterol levels in the tumor tissues in cancer patients.  
2.0 Materials and Method 
In all the subjects, venous blood samples were collected after overnight fasting into tubes containing 
Lithium heparine for lipid profile assay. The samples were centrifuged to separate the serum from the blood plasma. 
The serums obtained were stored by refrigeration until the analyses were carried out. 
Randox compact kits were employed for measurement of TC, TG, CHD-L and LDL-C. The instructions 
provided by the manufacturer were strictly observed to minimize variation. 
 
Procedure for total cholesterol assay 
The serum was mixed well and incubated at 37 for 5 minutes after which it was removed from the water 
bath and cooled to room temperature. The spectrophotometer was set to zero by using double distilled was as blank 
at 540nm wavelength. The absorbance of the standard and those of the serum samples were similarly obtained at 
540nm using 1ml of reagent and sample in a cuvette of 1cm pathlenght.   
Procedure for triglyceride assay 
The serum was well mixed and incubated at 37 for 5 minutes. Using fresh double distilled water as 
blank; the spectrophotometer was set to zero. The absorbances of the standard and sample were similarly obtained 
using 1000 of reagent with 10 of standard and 10 of sample respectively. 
Procedure for HDL-C assay 
Direct method of analysis was adopted for measuring of HDL-C concentration in serum sample without 
sample pretreatment.200ml of serum was well mixed with 500ml of precipitant. The mixture was allowed to sit for 
10 minutes at room temperature and the centrifuged. The cleared supernatant was separated after 2hours and the 
cholesterol content of the supernatant was determined by CHOD PAP Method. After calibration of the 
spectrophotometer, a mixture of 100 of standard and sample were separately added to 1000 of reagent to obtain 
reading at 540nm 
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 Determination of concentration LDL-C 
LDL-C = TC - TG/2.2 - HDL-C 
3.0 Results and Discussion 
The results of the laboratory analysis of serum sample from liver cancer patients and normal subjects for total 
cholesterol (TC), triglycrides (TG), high density lipoprotein cholesterol (HDL-c), low density lipoprotein cholesterol 
(LDL-C) concentration in mmol/l is presented in Table 3.0 while the result of atherogenic risk ratio (index) is 
presented in Table 3.1. 
 
Table 3.1: The concentrations of total cholesterol (TC), triglycrides (TG), high density lipoprotein cholesterol 










































 Unit of Measurement mmol/l 
S/NO TCp TCn TGp TGn HDLCp HDLCn LDLCp LDLCn 
1 5.22 3.4 0.82 2.00 0.86 0.7 3.99 1.8 
2 5.93 3.6 1.49 1.70 2.23 1.1 3.03 2.7 
3 5.78 5.2 1.05 1.50 2.02 2.2 3.28 2.3 
4 6.3 4.7 2.16 1.10 2.25 1.2 3.06 2.8 
5 3.8 4.9 0.85 1.20 1.76 1.8 1.63 2.6 
6 2.18 3.7 0.92 1.90 0.65 1.2 1.11 1.6 
7 4.68 4.1 0.98 1.00 2.41 2.1 3.55 1.5 
8 6.49 3.7 0.78 1.60 2.69 2.1 3.44 0.9 
9 5.65 4.2 0.504 0.07 2.34 2.0 3.08 1.9 
10 6.41 3.8 2.34 2.10 3.15 2.0 2.19 0.8 
 Atherogenic  Risk Ratio 
S/NO TCp/HDLCp TCn/HDLCn 
1 6.0698 4.8571 
2 2.6592 3.2727 
3 2.8614 2.3636 
4 2.8000 3.9167 
5 2.1591 2.7222 
6 3.3538 3.0833 
7 1.9419 1.9524 
8 2.4126 1.7619 
9 2.4145 2.1000 
10 2.0349 1.9000 
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Table 3.3: ANOVA analysis of total cholesterol (TC) concentrations in serum of liver cancer         
















1 5.22 27.2484 3.4 11.56 
2 5.93 35.1649 3.6 12.96 
3 5.78 33.4084 5.2 27.04 
4 6.3 39.69 4.7 22.09 
5 3.8 14.44 4.9 24.01 
6 2.18 4.7524 3.7 13.69 
7 4.68 21.9024 4.1 16.81 
8 6.49 42.1201 3.7 13.69 
9 5.65 31.9225 4.2 17.64 
10 6.41 41.0881 3.8 14.44 
Total 52.44 291.7372 41.3 173.93 
Mean 5.244  4.13  





Table 3.4: Summary of Statistical Analysis of The mean, ANOVA F-ratios and Duncan’s multiple range tests of 
results of TC, TG, HDL-C, LDL-C and TC/HDL-C for both liver cancer patients and normal subjects  
 MEAN ANOVA Duncan’s MRT 
 Mp Mn F-cal F-tab Sig. of dif. LSR DBM Sig. of dif. 
TC 5.244 4.130 5.56 4.41 Sig. 0.993 1.114 Sig. 
TG 1.189 1.417 0.07 4.41 Not Sig. 0.572 0.228 Not Sig. 
HDL-C 2.036 1.640 1.78 4.41 Not Sig. 0.624 0.396 Not Sig. 
LDL-C 2.836 1.890 6.73 4.41 Sig. 0.776 0.946 Sig. 
TC/HDL-C 2.871 2.793 0.02 4.41 Not Sig. 1.040 0.078 Not Sig. 




Table 3.5: Summary of results of coefficient of Variation (CV%) and Student T-test for TG,         HDL-C, 
LDL-C AND TC/HDL-C 
 Mean Standard 
deviation 
variance Coefficient of 
variation 
Student t-test 




 CVp% CVn% T-cal T-tab Sig. dif. 
TC 5.224 4.130 1.364 0.611 1.860 0.373 26 15 2.36 2.26 Sig. 
TG 1.189 1.417 0.613 0.605 0.376 0.366 51 43 0.84 2.26 Not sig. 
HDL-C 2.036 1.640 0.772 0.536 0.596 0.287 38 33 1.33 2.26 Not sig. 
LDL-C 2.836 1.890 0.907 0.713 0.822 0.508 32 38 2.59 2.26 Sig. 
TC/HDL-C 2.871 2.793 1.202 1.004 1.445 1.008 42 36 0.16 2.26 Not sig. 
 
 Total cholesterol (TC) 
The total cholesterol of most of the liver cancer patients was higher than those of the normal subjects. 
However, three liver cancer patients were found to have total cholesterol value above 6.21mmol/l. These individuals 
were at higher risk of coronary heart diseases (CHD) according to National Cholesterol Education Program (NCEP) 
Adult Treatment Panel II, 2001 recommendation which stated that TC value higher than 6.21mmol/l indicates high 
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risk of CHD. Also three cancer patients had TC values less than 5.17mmol/l which is the desirable recommended 
level by NCEP ATP II, 2001 National Institution of Heart (NIH), 1995. The remaining four patients were within 
borderline 5.17-6.18mmol/l as recommended by NCEP ATP II, 2001. 
All the normal subjects used as control had TC value less than 5.17mmol/l except one with 5.2mmol/l. the 
result of the Analysis of Variance (ANOVA) from Table 3.4 showed that the difference between the TC level of liver 
cancer patients and normal subjects was significant as the F-calculated value (5.56) was higher than F-table value 
(4.41) obtained under probability of 0.05 (5%). Similarly, the Duncan’s multiple range test (DMRT) showed that the 
difference between means (DBM= 1.114) TC of liver cancer patients and normal subjects was significant when 
compared to least significant range (LSR= 0.993). Also, the student t-test result showed that under 0.05 probability, 
the calculated t-value (2.357) was significant being higher than t-table value (2.26). From the coefficient of variation 
(CV%), it was revealed that result of TC of the normal subjects were more uniform than those of the liver cancer 
patients. 
Thus, it could be concluded from this study that liver cancer have significant effect TC or could alter TC level. The 
result from this study was similar to those reported by Alsabti et al., 1979, Cooper et al., 1996, who observed 
varying degree of difference in TC of patients suffered from hepatocellular carcinoma (liver cancer). 
 Triglyceride (TG) 
The triglyceride concentrations of both liver cancer patients and the normal subjects were low and within 
acceptable range. The TG value of the liver cancer patients range from 0.78-2.16mmol/l which was far lower than 
the 2.8mmol/l recommended by NIH, 1993 and NCEP ATP II, 2001. Similarly, the range of TG in normal subjects 
range from 0.07-2.1mmol/l. This might be an indication that liver cancer have little significance on TG. 
From table 3.4, the ANOVA result for TG showed no significant effect as the F-cal. Value (0.07) was very low 
compared to F-tab (4.41). The Duncan’s multiple range test showed that DBM of means of TG of normal subject and 
liver cancer patients (0.228) for TG was not significant when compared to LSR (0.572). 
From Table 3.5, the student t-test also showed that there was no significant difference between the means of 
TG of the liver cancer patients and the normal subjects as the Tcal. (0.84) was less than T-tab (2.26). CV% showed a 
relative average uniformity in both the normal subjects and the liver cancer patients. The result obtained for TG were 
similar to those reported by Alsabti et al., 1979, who reported that there was no observable change in TG of liver 
cancer patient compare to normal subjects. 
High density lipoprotein cholesterol (HDL-C) 
High density lipoprotein cholesterol was higher in live cancer patients compared to those of the normal 
subjects. However, two liver cancer patients and one normal subject have HDL-C value lower than the recommended 
value of 1.03mmol/l by NCEP ATP II, 2001. This is a strong indication of coronary heart disease (CHD) as low level 
of HDL-C may increase the risk of CHD.  
The ANOVA result of HDL-C showed that F-cal (1.78) was less than F-tab. (4.41), thus, the difference in 
the HDL-C of liver cancer patients and of normal subjects was not significant. The result of Duncan’s multiple range 
test showed the DBM (0.396) of HDL-C of both liver cancer patients and normal subject was not significant being 
less than LSR (0.624). The student t-test result also buttress the fact that there was no significant difference between 
the HDL-C means of the liver cancer patients and the normal subjects. CV% showed fairness in uniformity of 
HDL-C in both the normal subjects and the liver cancer patients.  The result of the analysis showed that the effect 
of liver cancer was minimal on HDL-C level in the subjects examined in this study. This was in accordance with 
report of Motta et al., who reported that there was no significant difference between HDL-C of normal and 
hepatocellular carcinoma patients (Motta et al., 2003).   
Low density lipoprotein cholesterol (LDL-C) 
The level of low density lipoprotein cholesterol in the liver cancer patients ranged from 1.11 to 3.99mmol/l 
was higher than that in the normal subjects in this study, which ranged from 0.8 to 2.8mmol/l. Although the level of 
LDL-C was higher, the values were with the borderline of 3.64-4.11mmol/l reported by NCEP ATP II, 2001. This 
was indicative that majority of the liver cancer patients were at risk of developing CHD  
The ANOVA result of LDL-C showed that F-cal (6.73) was higher than F-tab. (4.41), thus, the difference in 
the LDL-C of liver cancer patients and of normal subjects was significant. The result of Duncan’s multiple range test 
showed the DBM (0.946) of HDL-C of both liver cancer patients and normal subject was significant being higher 
than LSR (0.766). The student t-test result also underscred the fact that there was significant difference between the 
LDL-C means of the liver cancer patients and the normal subjects. CV% showed fairness in uniformity of LDL-C in 
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both the normal subjects (CV% = 38) and the liver cancer (CV% = 32) patients.  The result of the analysis showed 
that the effect of liver cancer was of high significance on LDL-C level in the subjects examined in this study. The 
report of Motta et al., 2003 supported the findings of this study because they reported that hepatocellular carcinoma 
in liver cancer patients significantly affected LDL-C level when compared to that of normal subjects  
Atherogenic risk ratio (TC/HDL-C) 
The atherogenic risk ratio calculated as the ratio of TC to HDL-C is an indicator for coronary heart disease 
(CHD). According to Cooper et al., 1996, atherogenic ratio greater than 6.0 indicates high risk of CHD. The 
atherogenic risk ratio among the subjects examined was very low except a liver cancer patient with risk ratio 6.07.  
From table 3.4, the ANOVA result for atherogenic risk ratio showed no significant effect as the F-cal. Value 
(0.02) was very low compared to F-tab (4.41). The Duncan’s multiple range test showed that DBM (0.078) of means 
of atherogenic risk ratio of normal subject and liver cancer patients for atherogenic risk ratio was not significant 
when compared to LSR (1.040). 
From Table 3.5, the student t-test also showed that there was no significant difference between the means of 
atherogenic risk ratio of the liver cancer patients and the normal subjects as the Tcal. (0.157) was less than T-tab 
(2.26). CV% showed a relative uniformity in both the normal subjects and the liver cancer patients. The result 
obtained for atherogenic risk ratio was similar to those reported by Buendia, 1992. 
4.0 Conclusion 
The statistical analysis showed that liver cancer significantly affect the concentration of TC and LDL-C but 
have minimal effect on the TG, HDL-C and Atherogenic risk ratio. This result showed that liver cancer had effect on 
some parameters of lipid profile and might have negative influence on the management of coronary heart disease 
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